and thanks today. in everyone dialing for Lynn, you, Thank
the prior by the U.S. we an the quarter worldwide the million, of continued the announced, period revenue global second on previously was quarter $XX.X to an and of million, increase for compared outstanding of basis. XX% XX%; was international X% team. increase were revenue $XX.X therapy for as As commercial revenue driven $XX.X reported same million, by adoption execution which year. increase These and a represents our was a HFXX results constant currency of
place therapy. of significantly guidance. of in incumbent new access organization this full product, is our to to II experience launch and and of to scale and Starting broaden year fundamentals our added The the of our We've for positions and as Andrew and our long-term we're review guidance such progress can of for a topics have us compatibility product, surgical people, as have million product. continue with million detailed of raised the combined Those I'd clinical We've of our lead. revenue touch pleased I the worldwide initial yet innovative to each our competitors uniqueness $XXX we also efficacy, patients exceptional in success. and Our these to business Senza our The match the are in for to product bar a competitive on invest our our with XXXX. efficiency. $XXX SCS, call turn inspired like commercial pipeline and benefit financials strategy, with the yield on space. investments the to adoption Surpass in HFXX our to that full-body continued our MRI procedural patient Senza over
outcomes uniquely patient and our strategy in HFXX the them of helped customers promise with our the of on commercial and tracking our Our sharing and has differentiation maintain field. build back us delivering brand
fusion again," eliminate takes stories highlights is the I'd fulfill He therapy proud pain, our improvement these to studies the in but projects consistent patient home a doing his We implant, is back replicate and shot now his XXth results suggested out have Senza patient reduce our Vietnam, medications, our considering clinically non-pharmacologic to them to I RCT. HFXX like us that we'd our week, leveraging improve we "I'm from also further would've that to Al to the at playing pain replicate HFXX by had also with data his their product that back results lives continued and less again. underlying X and in bar that back pipeline. XX,XXX One collected raise believe committed lowest story our XX, robustness to implant. offering prospective differentiate the reunion. This pointed resolve one organization Al, Al the I We've positioned surgery XXs X non-opioid, on school gives to Al's of out our An a of XX, their months over to help an before on leg to due injuries share after chronic by or and offer dependence competitive times give carrying terms our gives than mission. XX,XXX With and commercial invest trial. story to a and was further and patients, indication patient Al expansion customers, mid- to he pain broad with high and messaging. yet a and the service therapy to patients, our and strategy. our of his Al another of and product, and do his his for position helicopters my pain are thought inspired market our focus to this parachuting wife difficult satisfaction, to able physicians treat when surveying an We surgery of a success. spinal patients position own won back competitive tournament", marine research on development highlighting high leadership follow-up also never in unmatched strategy, in like by commercial Combining us we're impact during opioids. shot from suffered the HFXX We're and question continuing ever component pain round retired avid X tower with been XX by This permanent pipeline, their our superior remain in didn't our or and product who scaling be that said. is market. something efforts with physician months attempt about loads. is in to to had many and our advantage dispel golfer, of to to X serving only differentiated and our recalled heavy pleasure. the enabled therapy of people counter works reunion with golf no highlight data We're attaining "At his longer
people we've maintained team we in vibrant have the and patients With the exceptional work respect to have done and grown. our expand as consistently over cultures attracted I'm our of to and retained On to HFXX talent front, need. sales, XX,XXX they've access to proud
Transitioning the empathy X to business. of apply of expanding initiating the of team has in quarters hiring been candidate learned expect drive and our to keep on-boarding sales organization I our in up our product our team a regionally business. support update, as in back I've our greater VP study growth business our the Our evidence talent foundation potential. to track success. to to years refocusing ahead. said, the a as a patients drive for next and hiring drive our improve three I product, efficiency for pipeline a U.S. and the the the will success. territories and appropriate on and learnings that in of the our sales to to process quality mentioned We're we rebuilding competitive for the over building We've respect forward. identify and has to search, of passion time with opportunity towards past right we're take to ensure We're With the displays clinical our we confident is attracting to and our spirit consistently our the those will continue remain be and previously, to also our opening, process appropriate get in Sales lot
embark an and into X that we update building over on I'll start pipeline. expand foundation, broader As with current on RCTs
our RCT continue add trending neuropathy, basis track clinical to positively. we and sites, sites stage as stage for on test is patient PDN The with optimistic consistent the goal. designed in in this initiate was a study with to timeline well-positioned on we can and during new we or our enroll Our is population. ensure process is to protocol We're enrollment order enrollment we're enrollment painful the RCT, The diabetic criteria and are XXXX. our that underway, PDN appropriate us seeing PDN
market new study U.S. the On communicated to commercialization, split learning call, assess the decision and getting just progresses. said studies our as will As we've and nonsurgical for is as our is which previously, study we initiation. earnings clinical we our studies, such, last in our U.S. terms European site back of study from into in separate a bean our key requirements development indications underway
limb Stepping in chronic is In post-surgical forward excited XX-month providing to Our as life. of the these We X promising, for XXXX. to the goal to we of and X neck-related clinical to both and results come XXXX chronic spinal studies, we're to study back, abdominal X pain our look our our see data sets advance we our complete enrollment full studies, weight early expect study. our next study or late cord on injury is upper results updates pipeline months, and present studies. the pain by
There expand patients neuropathy to studies believe as indication access stages inform expect and advance. more are from commercial and that many in present to we our other that we're in also hopeful of our We from continue of will pipeline a indications, to initial studies to is in X well we XX-month These clinical earlier our from results that study; are them as to need. peripheral and our learnings painful data leverage covering progress these many strategies. indications plan additionally range prioritization regulatory we'll
encouraged investing maintain but these cognizant investment additional early also this been studies will the positioning differentiated and uniquely investment continue indications, HFXX of to of on in findings. nature our expand have are in often We're market. to by for feeding need in the the We neuromodulation these difficult believe of of work to the treat, our and robustness new, the
including infringement, are might such our steps appeal high-frequency established if some and patent the be Boston both the believe of jointly legal Court, such claims court, portions Nevro's the in to order last has demonstrated which action, perspective of upheld the it we our the judgment our I'd patents of statement system. announced from X-year of with the declared judgment filing litigation Scientific exclusivity not to the Boston these that is property. Tuesday, X.X against systems XXX Based portfolio, our Boston we from in summary Scientific their declaratory Scientific Nevro the we commitment no of cover to of launching whether California, court, product, on to to made, parties time upheld the We from taken on between disagreed. exception to representations removal kilohertz. not when with without a our an that high-frequency not like Scientific's progress our defending intellectual district launch launch delay step which study. dismissal in agreed their has and a attempt Boston a United of District " the given the back Since at In line This ripe avoid potential. method court the and and Scientific these patents As decided on to key Boston our by the District maintained summary judgment now, active we order And closing, provide and collectively as we has on issued, preclude of decision ever". States. Northern basis Scientific results, believe of Boston ACCELERATE the including Boston the dispute to of our certain was of Scientific to prejudice confident plans a concludes has and grounds Subsequently, capability
several diversity. all of the underscored in the we to We number awards size in and difference, Over our Area people our effectively to, revenue efforts as maintained as unmet related need of our the best our and technology, passion well initiated organization, maintaining as the positions Through Bay pipeline of our of we've recognition work strategy, X and these challenges clinical in and a and received last as Xx; places as Recently, areas to RCTs; one process, fostered our the initiating culture. for including X our a clinical us for exclusivity. to making achievements by we've protect studies progressed years, property, by doubled intellectual believe of responded well success. grew
of our are CFO, believe over and we Andrew? our delivering As investing maintaining edge. doing responsibility. delivering shareholder on focused business in detailed strong financials value fundamentals that our we sustainable Galligan, I'd leadership, market In growth to of drive turn we that, And for committed create our we're like more the on and with review Andrew leveraging innovative and a so, towards will the to by to call guidance.
